On The Path
To a Cure

Developing a gene therapy
for Lowe syndrome





Meet Walther











Pioneering gene therapy research for Lowe Syndrome










Focused 
on a cure



At Cure Lowe Foundation we work on one thing: treatments that address the cause of Lowe syndrome. Our lead programme, a gene therapy for the kidney, is now in development at Walther Therapeutics, the drug development company the foundation owns. Alongside it we support early research into a stem-cell gene therapy and into existing medicines that might help sooner.

See our research










Lowe Syndrome

A Multiorgan Challenge

  Lowe syndrome is a devastating rare genetic disorder that primarily affects young boys. Caused by mutations in the OCRL gene, this condition creates life-altering challenges:

   
Vision problems that can lead to blindness
   
Neurological complications affecting development
   
Severe kidney dysfunction requiring constant care

Currently, families face an uphill battle: available treatments only manage symptoms without addressing the root cause. Each day brings new challenges for these brave children and their dedicated families.

But there's hope on the horizon. Through groundbreaking gene therapy research, we're working to not just treat symptoms, but to transform lives. With your support, we can turn this hope into reality.

Questions and answers







Our scientific team is unmatched in expertise




 
Dr.  Siyu  Chen  working in the lab 











Cure Lowe Foundation brings together scientists, drug developers and patient advocates. Members of our team have worked on approved gene therapies such as Hemgenix and Glybera, and on more than a decade of research into Lowe syndrome.









Want to be part of the solution?